These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8847879)

  • 1. Rate-dependent effects of the class III antiarrhythmic drug almokalant on refractoriness in the pig.
    Wiesfeld AC; De Langen CD; Crijns HJ; Bel KJ; Hillege HL; Wesseling H; Lie KI
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):594-600. PubMed ID: 8847879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiological, rate dependent, and autonomic effects of the class III antiarrhythmic almokalant after myocardial infarction in the pig.
    Tuininga YS; De Langen CD; Crijns HJ; Wiesfeld AC; Mook PH; Bel KJ; Lie KI
    Pacing Clin Electrophysiol; 1996 May; 19(5):802-10. PubMed ID: 8734747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Ik blocker almokalant exhibits class III--specific effects on the repolarization and refractoriness of the human heart: a study of healthy volunteers using right ventricular monophasic action potential recordings.
    Darpö B; Vallin H; Almgren O; Bergstrand R; Insulander P; Edvardsson N
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):530-40. PubMed ID: 8569212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerance and effects of almokalant, a new selective Ik blocking agent, on ventricular repolarization and on sino-atrial and atrioventricular nodal function in the heart: a study in healthy, male volunteers utilizing transesophageal atrial stimulation.
    Darpö B; Almgren O; Bergstrand R; Bäärnhielm C; Gottfridsson C; Sandstedt B; Edvardsson N
    J Cardiovasc Pharmacol; 1995 May; 25(5):681-90. PubMed ID: 7630145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans.
    Dorian P; Pinter A; Mangat I; Korley V; Cvitkovic SS; Beatch GN
    J Cardiovasc Pharmacol; 2007 Jul; 50(1):35-40. PubMed ID: 17666913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
    Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
    Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electropharmacologic effects and pharmacokinetics of almokalant, a new class III antiarrhythmic, in patients with healed or healing myocardial infarcts and complex ventricular arrhythmias.
    Wiesfeld AC; Crijns HJ; Tobé TJ; Almgren O; Bergstrand RH; Aberg J; Haaksma J; Lie KI
    Am J Cardiol; 1992 Oct; 70(11):990-6. PubMed ID: 1384304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of frequency dependency of the class III effects of almokalant: a study using programmed stimulation and recording of monophasic action potentials and ventricular paced QT intervals.
    Darpö B; Almgren O; Bergstrand R; Franzén S; Edvardsson N
    Cardiovasc Drugs Ther; 1996 Nov; 10(5):539-47. PubMed ID: 8950068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.
    Carlsson L; Abrahamsson C; Andersson B; Duker G; Schiller-Linhardt G
    Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans.
    Sager PT; Follmer C; Uppal P; Pruitt C; Godfrey R
    Circulation; 1994 Oct; 90(4):1811-9. PubMed ID: 7923666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrophysiologic effects of intravenous MS-551, a novel class III antiarrhythmic agent, on human atrium and ventricle.
    Naitoh N; Taneda K; Tagawa M; Furushima H; Yamaura M; Aizawa Y
    Jpn Heart J; 1998 May; 39(3):297-305. PubMed ID: 9711181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of almokalant, a class III antiarrhythmic agent, on supraventricular, reentrant tachycardias. Almokalant Paroxysmal Supraventricular Tachycardia Study Group.
    Darpö B; Edvardsson N
    Cardiovasc Drugs Ther; 1997 Jul; 11(3):499-508. PubMed ID: 9310280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent.
    Bargheer K; Bode F; Klein HU; Trappe HJ; Franz MR; Lichtlen PR
    Eur Heart J; 1994 Oct; 15(10):1409-14. PubMed ID: 7821321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiologic and hemodynamic effects of H 234/09 (almokalant), quinidine, and (+)-sotalol in the anesthetized dog.
    Duker G; Almgren O; Carlsson L
    J Cardiovasc Pharmacol; 1992 Sep; 20(3):458-65. PubMed ID: 1279293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency-dependent electrophysiologic effects of amiodarone in humans.
    Sager PT; Uppal P; Follmer C; Antimisiaris M; Pruitt C; Singh BN
    Circulation; 1993 Sep; 88(3):1063-71. PubMed ID: 8353868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiologic effects of a new class III antiarrhythmic agent, E-4031, on atrial flutter, atrial refractoriness, and conduction delay in a canine sterile pericarditis model.
    Shimizu A; Kaibara M; Centurion OA; Kapuku G; Hirata T; Fukatani M; Yano K; Hashiba K
    J Cardiovasc Pharmacol; 1993 Apr; 21(4):656-62. PubMed ID: 7681913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the acute electrophysiologic effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias.
    Verduyn SC; Vos MA; Leunissen HD; van Opstal JM; Wellens HJ
    J Cardiovasc Pharmacol; 1999 Feb; 33(2):212-22. PubMed ID: 10028928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolongation of the QT interval by dofetilide modulates rate-dependent effects of mexiletine on intraventricular conduction.
    Todt H; Zojer N; Raberger G; Schütz W
    Eur J Pharmacol; 1994 Nov; 265(1-2):43-52. PubMed ID: 7883028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiological effects of E 4031, a drug with selective class III properties, in man.
    Katritsis D; Morgan J; Brachmann J; Bygrave A; O'Farrell D; Rowland E; Camm AJ
    Pacing Clin Electrophysiol; 1997 Apr; 20(4 Pt 1):930-7. PubMed ID: 9127398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use-dependent electrophysiologic effects of DL-sotalol and modulation by isoproterenol in the human ventricle.
    Naitoh N; Furushima H; Ohira K; Taneda K; Aizawa Y
    Jpn Heart J; 1998 Mar; 39(2):153-61. PubMed ID: 9687824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.